Gem Pharmaceuticals announced that the Food and Drug Administration has granted Orphan Drug designation to GPX-150 for the treatment of soft tissue sarcoma (STS).
GPX-150 is currently undergoing a Phase 2 clinical trial to assess its efficacy and safety in adult patients with STS as first-line therapy for advanced or metastatic disease. The primary endpoint is progression-free rate at 12 months. Final results are expected to be available by the fourth quarter of 2016.
RELATED: Pexidartinib Designated Breakthrough Therapy for Rare Tumor
STS includes a group of malignancies that affect tissues such as fat, muscles, nerves, and tendons.
For more information visit Gempharmaceuticals.com.
